-
公开(公告)号：EP2605789B1
公开(公告)日：2019-06-05
申请号：EP11818758.2
申请日：2011-08-17
申请人： Ambrx, Inc.
-
2.发明公开COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES 审中-公开组合物，工艺与和自然科学使用具有不连接的氨基酸衍生物多拉司他汀
公开(公告)号：EP3170821A1
公开(公告)日：2017-05-24
申请号：EP16188163.6
申请日：2012-05-24
申请人： Ambrx, Inc.
发明人： MIAO, Zhenwei , ATKINSON, Kyle, C. , BIROC, Sandra , BUSS, Timothy , COOK, Melissa , KRAYNOV, Vadim , MARSDEN, Robin , PINKSTAFF, Jason , SKIDMORE, Lillian , SUN, Ying , SZYDLIK, Agnieszka , LOPEZ DE VALENTA, Delia Ianina
IPC分类号： C07D417/12 , C07D401/12 , C07D207/325 , A61K31/427 , A61P35/00 , C07K5/02 , A61K39/00 , C07K16/28 , C07K5/06 , A61K31/337 , A61K39/395
CPC分类号： C07K5/06 , A61K31/337 , A61K31/427 , A61K39/39558 , A61K47/6803 , A61K47/6855 , A61K2039/505 , C07D207/325 , C07D401/12 , C07D417/12 , C07K5/02 , C07K16/2896 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
摘要翻译： 公开在可用于制备寻求非天然氨基酸和多肽的非天然氨基酸和多拉司他汀类似物也包括至少一个非天然氨基酸，和方法。 多拉司他汀类似物可包括宽范围的可能的功能性的，但典型地具有至少一个肟，羰基，二羰基，和/或羟胺基团。 因此游离缺失盘是在非天然氨基酸多拉司类似物没有被翻译后修饰此外，方法用于实现寻求修改，并寻求多拉司他汀类似物的净化方法。 典型地，修饰的多拉司他汀类似物包括至少一个肟，羰基，二羰基，和/或羟胺基团。 进一步游离缺失光盘是使用搜索非天然氨基酸多拉司他汀类似物和多拉司他汀的经修饰非天然氨基酸类似物，包括治疗，诊断和其它生物技术使用的方法。
-
公开(公告)号：EP2076533B1
公开(公告)日：2014-10-08
申请号：EP08747233.8
申请日：2008-04-30
申请人： Ambrx, Inc.
发明人： KRAYNOV, Vadim , KNUDSEN, Nick , HAYS PUTNAM, Anna-Maria A. , KRAWITZ, Denise , PINKSTAFF, Jason , MYLER, Heather
IPC分类号： C07K14/565 , A61K38/21
CPC分类号： C07K14/565 , A61K38/00
-
公开(公告)号：EP2820034A1
公开(公告)日：2015-01-07
申请号：EP13755219.6
申请日：2013-02-27
申请人： Ambrx, Inc.
IPC分类号： C07K14/00
CPC分类号： C07K14/575 , A61K38/00 , C07K14/5759
摘要： Modified adiopnectin polypeptides and uses thereof are provided.
-
5.发明公开COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES 审中-公开成分与链接多拉司他汀衍生物非天然氨基酸和方法含有这些物质及其用途
公开(公告)号：EP2714684A1
公开(公告)日：2014-04-09
申请号：EP12793246.5
申请日：2012-05-24
申请人： Ambrx, Inc.
发明人： MIAO, Zhenwei , ATKINSON, Kyle, C. , BIROC, Sandra , BUSS, Timothy , COOK, Melissa , KRAYNOV, Vadim , MARSDEN, Robin , PINKSTAFF, Jason , SKIDMORE, Lillian , SUN, Ying , SZYDLIK, Angieszka , LOPEZ DE VALENTA, Ianina
IPC分类号： C07D417/12 , C07D207/08 , C07D401/12 , A61K31/427 , A61P35/00
CPC分类号： C07K5/101 , A61K38/07 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6855 , A61K47/6861 , C07D207/08 , C07D401/12 , C07D417/12 , C07K5/0205 , C07K5/06043
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
-
公开(公告)号：EP1893229B1
公开(公告)日：2011-10-19
申请号：EP06772153.0
申请日：2006-06-02
申请人： Ambrx, Inc.
发明人： HAYS PUTNAM, Anna-Maria, A. , KIMMEL, Bruce, E. , CHO, Ho, Sung , SIM, Bee-cheng , LITZINGER, David, C. , MARIANI, Roberto , KRAYNOV, Vadim , KNUDSEN, Nick , DANIEL, Thomas, O. , KODER, Alan , BUSSELL, Stuart , LIU, Junjie , MIAO, Zhenwei , MORROW, Theresa
IPC分类号： C07K14/56
CPC分类号： C07K14/555 , A61K38/00 , C07K14/56
摘要： Modified human interferon polypeptides and uses thereof are provided.
-
公开(公告)号：EP2247743A2
公开(公告)日：2010-11-10
申请号：EP09709283.7
申请日：2009-02-05
申请人： AMBRX, INC.
发明人： KRAYNOV, Vadim , PUTNAM, Anna-Maria, A., Hays , KNUDSEN, Nick , PINKSTAFF, Jason , MYLER, Heather , SULLIVAN, Lorraine
CPC分类号： C07K14/5759
摘要： Modified human leptin polypeptides and uses thereof are provided.
-
8.发明授权COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES 有权成分与链接多拉司他汀衍生物非天然氨基酸和方法含有这些物质及其用途
公开(公告)号：EP2714685B1
公开(公告)日：2016-10-19
申请号：EP12793459.4
申请日：2012-05-24
申请人： Ambrx, Inc.
发明人： MIAO, Zhenwei , ATKINSON, Kyle, C. , BIROC, Sandra , BUSS, Timothy , COOK, Melissa , KRAYNOV, Vadim , MARSDEN, Robin , PINKSTAFF, Jason , SKIDMORE, Lillian , SUN, Ying , SZYDLIK, Agnieszka , LOPEZ DE VALENTA, Delia Ianina
IPC分类号： C07D417/12 , C07D401/12 , C07D207/325 , A61K31/427 , A61P35/00 , C07K5/02 , A61K39/395 , A61K47/48 , A61K31/337 , C07K5/06 , C07K16/28 , A61K39/00
CPC分类号： C07K5/06 , A61K31/337 , A61K31/427 , A61K39/39558 , A61K47/6803 , A61K47/6855 , A61K2039/505 , C07D207/325 , C07D401/12 , C07D417/12 , C07K5/02 , C07K16/2896 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
-
公开(公告)号：EP2247743B1
公开(公告)日：2016-04-06
申请号：EP09709283.7
申请日：2009-02-05
申请人： AMBRX, INC.
发明人： KRAYNOV, Vadim , PUTNAM, Anna-Maria, A., Hays , KNUDSEN, Nick , PINKSTAFF, Jason , MYLER, Heather , SULLIVAN, Lorraine
CPC分类号： C07K14/5759
摘要： Modified human leptin polypeptides and uses thereof are provided.
-
10.发明公开COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES 有权含有的组合物，涉及非天然氨基酸连接的松香衍生物的方法和用途
公开(公告)号：EP2714685A1
公开(公告)日：2014-04-09
申请号：EP12793459.4
申请日：2012-05-24
申请人： Ambrx, Inc.
发明人： MIAO, Zhenwei , ATKINSON, Kyle, C. , BIROC, Sandra , BUSS, Timothy , COOK, Melissa , KRAYNOV, Vadim , MARSDEN, Robin , PINKSTAFF, Jason , SKIDMORE, Lillian , SUN, Ying , SZYDLIK, Agnieszka , LOPEZ DE VALENTA, Delia Ianina
IPC分类号： C07D417/12 , C07D401/12 , C07D207/325 , A61K31/427 , A61P35/00
CPC分类号： C07K5/06 , A61K31/337 , A61K31/427 , A61K39/39558 , A61K47/6803 , A61K47/6855 , A61K2039/505 , C07D207/325 , C07D401/12 , C07D417/12 , C07K5/02 , C07K16/2896 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
摘要翻译： 本文公开了包含至少一个非天然氨基酸的非天然氨基酸和多拉司他汀类似物，以及制备此类非天然氨基酸和多肽的方法。 多拉司他汀类似物可以包括多种可能的官能团，但通常具有至少一个肟，羰基，二羰基和/或羟胺基团。 本文还公开了在翻译后进一步修饰的非天然氨基酸多拉司他汀类似物，实现这种修饰的方法和纯化这些多拉司他汀类似物的方法。 通常，修饰的多拉司他汀类似物包括至少一个肟，羰基，二羰基和/或羟胺基团。 进一步公开了使用这种非天然氨基酸多拉司他汀类似物和修饰的非天然氨基酸多拉司他汀类似物的方法，包括治疗，诊断和其他生物技术用途。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.049 秒)
